BioNTech explained

BioNTech SE
Type:Public
Traded As:NASDAQ:
Industry:Biotechnology
Hq Location City:Mainz
Hq Location Country:Germany
Num Locations:17
Num Locations Year:2024[1]
Area Served:Worldwide
Products:Pfizer-BioNTech COVID-19 vaccine, Immunotherapy and vaccine candidates
Services:Immunotherapy
Revenue:  billion
Revenue Year:2024
Operating Income: €-1.31 billion
Income Year:2024
Net Income: €-665 million
Net Income Year:2024
Assets: €22.53 billion
Assets Year:2024
Equity: €19.41 billion
Equity Year:2024
Num Employees: 6,772
Num Employees Year:2024
Footnotes:BioNTech FY 2024 report[2]

BioNTech SE (; or [3] short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology[4] testing combination therapy approaches to improve treatment outcomes. In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic.[5] [6]

History

Foundation (2008–2014)

BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci,[7] and Christoph Huber,[8] with a seed investment of €180 million[9] from MIG Capital, a Munich-based venture capital firm, the family office of Andreas and Thomas Strüngmann, and the present chairman of the supervisory board, Helmut Jeggle.[10] [11] [12] In 2009, the acquisition of EUFETS and JPT Peptide Technologies took place.[13] The company's origins lie in research conducted by Şahin, Türeci, and their teams, who over several decades made progress in addressing challenges using messenger RNA (mRNA) as a therapeutic. Their aim was to utilize mRNA for the development of individualized cancer immunotherapies. They focused on overcoming issues such as mRNA's limited stability in the body, developing formulations to effectively deliver mRNA to target cells, and improving protein production, which was initially low and short-lived.[14] In 2013, Hungarian biochemist Katalin Karikó, who later shared the 2023 Nobel Prize in Physiology or Medicine,[15] joined BioNTech as a senior vice president. She later stayed an external advisor.[16] Karikó discovered that modifying the nucleotide uridine could reduce the immunogenicity of mRNA, making it more suitable for therapeutic use.[17] All of these scientific discoveries were utilized in BioNTech's mRNA-based drug development.

Expansion, Series A financing (2015–2018)

Between 2014 and 2018, research results on mRNA mechanisms were published by BioNTech. Collaborations and commercialization agreements were concluded with various companies and scientific institutions starting in 2015.[18] In January 2018, BioNTech closed a million Series A financing round to further expand the company's immunotherapy research.[19] In August 2018, the company entered into a multi-year research and development (R&D) collaboration with the US company Pfizer, Inc. to develop mRNA-based vaccines for prevention of influenza. Under the terms of the agreement, following BioNTech's completion of a first-in-human clinical study, Pfizer would assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines.[20]

Series B financing and Nasdaq IPO (2019)

In July 2019, Fidelity Management & Research Company led a Series B investment round totalling US$325 million, with investments from new and existing investors, including Redmile Group, Invus, Mirae Asset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Strüngmann family office.[21] [22] In September 2019, BioNTech received a contribution of US$55 million from the Bill & Melinda Gates Foundation.[23] In December 2019, BioNTech received a €50 million loan to finance the development of its patient-specific immunotherapies for the treatment of cancer and other serious diseases, from the European Investment Bank (EIB) as part of the European Commission Investment Plan for Europe.[24] Since 10 October 2019, BioNTech has been publicly traded as American Depository Shares (ADS) on the NASDAQ Global Select Market under the ticker symbol BNTX. BioNTech was able to generate total gross proceeds of US$150 million from the IPO.[25]

COVID-19 (since 2020)

See also: Pfizer–BioNTech COVID-19 vaccine. BioNTech initiated "Project Lightspeed" in January 2020 to develop an mRNA-based COVID-19 vaccine, just days after the SARS-Cov-2 genetic sequence was first made public.[26] In March 2020, BioNTech partnered with Fosun Pharma for mainland China and the special administrative regions of Hong Kong and Macau and Pfizer for the rest of the world, excluding Germany and Turkey, where BioNTech retained exclusive rights.[27] Clinical trials began in April 2020 across multiple regions.[28] Due to the global situation caused by the pandemic and the need for a vaccine, BioNTech received financial support from the European Investment Bank (a €100 million loan in June 2020)[29] [30] [31] [32] and the German Federal Ministry of Education and Research (a €375 million grant).[33] BioNTech also received €250 million from Temasek Holdings (Singapore) in June 2020 via the purchase of ordinary shares and 4 years convertible notes, but also from other investors through a private placement of mandatory convertible bonds.[34] In November 2020, BioNTech and its partner Pfizer announced the vaccine's 95% efficacy, and by December, it received emergency use authorizations in the United Kingdom[35] [36] and the United States, followed by conditional marketing approval in the European Union.[37] After those steps, the large-scale vaccinations began. In August 2021, thanks to a meteoric rise in its share price, BioNTech's market capitalization briefly exceeded US$100 billion, making it one of the most valuable companies in Germany at that time.[38]

Oncology and international expansion (since 2021)

Alongside ongoing development of COVID-19 vaccines, BioNTech expanded its oncology pipeline and drug manufacturing capabilities,[39] [40] leading to an increasing number of trials in advanced clinical phases.[41] [42] [43] The company has formed strategic collaborations and acquisitions to enhance its platform technologies, global manufacturing capacity, and computational drug discovery capabilities.[44] [45] In 2023, BioNTech acquired InstaDeep, a British AI technology company, to strengthen its AI-driven approach in drug development. BioNTech had been collaborating with InstaDeep since 2019 on cancer drug design and expanded their partnership in 2022 to create an early warning system for detecting SARS-CoV-2 variants of concern.[46] [47] In February 2022, BioNTech introduced the BioNTainer, a modular system for decentralized and scalable production of mRNA-based medicines in various locations. The first BioNTainer-based manufacturing site was inaugurated in Kigali, Rwanda, in December 2023, marking BioNTech's first facility in Africa.[48] That same month, BioNTech announced a partnership with the Australian state of Victoria to build a BioNTainer-based clinical-scale mRNA manufacturing plant in Melbourne.[49] In 2023, BioNTech entered a collaboration with the UK government to expand access to personalized mRNA cancer immunotherapies in clinical trials, aiming to treat up to 10,000 patients by 2030.[50] [51]

In July 2024, BioNTech entered a collaboration with Triastek, a Chinese company specializing in 3D printing pharmaceuticals, to develop 3D-printed oral RNA therapeutics. The collaboration will harness Triastek’s capabilities in new oral tablet designs made possible by 3D printing.[52]

In December 2024, the Chinese biotech company Biotheus, with which a global licensing and collaboration agreement was already in place, was acquired for approximately one billion US dollars. As a result, BioNTech secures full rights to the drug candidate BNT327/PM8002, currently in advanced stages of clinical development.[53]

In June 2025, BioNTech has acquired CureVac, a German biopharmaceutical firm and a former rival in the COVID-19 vaccine race. The deal will be worth approximately $1.25 billion. BioNTech expects that this acquisition will further strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy.[54]

In January 2026, BioNTech announced a $50 million life science fund in partnership with the University of Pennsylvania. The Penn-BioNTech Innovative Therapeutics Seed (PxB) Fund will invest in seed and Series A companies with university researchers developing therapeutics, diagnostics, digital platforms and research tools.[55]

Company structure

Locations

BioNTech's founding place and global headquarters is Mainz, Germany.[56] Other sites in Germany are located in Berlin, Halle (Saale), Idar-Oberstein, Marburg, and Munich. The company operates several GMP-certified manufacturing sites across Germany.[57] [58] [59] BioNTech also operates international offices and manufacturing sites in Europe (Vienna, Austria; London, England; Cambridge, England),[60] North America (Berkeley Heights, U.S.; Cambridge, U.S.; Gaithersburg, U.S.),[61] Asia (Istanbul, Turkey; Singapore;[62] [63] Shanghai, China), Australia (Melbourne)[64] and Africa (Kigali, Rwanda).[65] [66]

Management Board

The management Board of BioNTech, as of July 2024, is made up of Uğur Şahin (Chief Executive Officer), Annemarie Hanekamp (Chief Commercial Officer), Jens Holstein (Chief Financial Officer), Sierk Poetting (Chief Operating officer), Ryan Richardson (Chief Strategy Officer), James Ryan (Chief Legal and Chief Business Officer) and Özlem Türeci (Chief Medical Officer).[67]

Therapeutic areas

Oncology

To enhance cancer treatment, BioNTech is developing combinations of multiplatform assets, including targeted therapies, immunomodulators, and mRNA-based therapies, with the aim of creating synergistic effects. By identifying novel cancer-specific or tumor-specific targets and integrating its platforms, BioNTech seeks to improve treatment outcomes across all stages of cancer.[68] [69] For example, the company is developing combination therapies, such as pairing CAR-T cell treatments with mRNA-based vaccines. These vaccines encode target structures that boost CAR-T cell activity and persistence, enhancing the overall treatment effectiveness.[70] In November 2023, in an interview to German broadcaster ZDF, BioNTech CEO Uğur Şahin said the company expects a mRNA-based therapeutic cancer vaccine approval by 2030.[71] BioNTech also announced in May 2024 that it expects to launch its first cancer therapies starting in 2026.[72]

Infectious diseases

BioNTech is developing mRNA-based vaccines for a range of infectious diseases with significant global health impact, including COVID-19, malaria, tuberculosis, and mpox.[73]

Criticism

Influence by the Chinese government

During an increase in COVID-19 infections in Taiwan in May 2021 and acute vaccine shortage, Taiwanese President Tsai Ing-wen accused the company of insisting on the deletion of the phrase "our country" during failed contract negotiations on vaccine deliveries.[74] However, a contract was not signed even then, when the demand was met.[75] This was interpreted by the media as, among other things, weakening the independence of the Republic of China and influencing BioNTech by the People's Republic. Others saw legal reservations as a trigger, since the Chinese company Fosun Pharma already had exclusive marketing rights, which also included the island territory of Taiwan.

Pricing of the COVID vaccine

Comirnaty BioNTech was criticized at the beginning of 2021 because of the pricing of its COVID vaccine Comirnaty: NDR, WDR and the Süddeutsche Zeitung reported that they had reports with an initial offer to the EU in June 2020 in the amount of 54.08 euros per vaccine dose.[76] The chairman of the Medicines Commission of the German Medical Association, Wolf-Dieter Ludwig, described the award as "dubious".[77] [78] However, BioNTech explained that 54.08 euros had never been intended as a concrete price for subsequent large-scale deliveries. The cost statement was based on the production processes at that time, before mass production began and the mRNA dosage was determined and reflected the costs at that time. The federal government stated at the price of 54.08 euros that "It was clear to everyone that this was not the real offer, but a water level report".

In August 2021, BioNTech set the price per dose at 19.50 euros, which was justified, among other things, by the necessary adjustments of the vaccine to new virus variants. Critics, on the other hand, claimed that BioNTech was simply using its market dominance to demand higher prices.[79]

See also

External links

49.9878°N 8.2713°W

Notes and References

  1. Web site: Locations . BioNTech . 2024-12-14.
  2. Web site: BioNTech 2024 Annual Report (Form 20-F) . 10 March 2025 . . 11 March 2025.
  3. Web site: BioNTech CEO on vaccine progress with Pfizer – YouTube. 10 November 2020 . 14 June 2021. YouTube.
  4. Web site: Amy Baxter . Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. . . 2024-08-14 . 2024-12-15.
  5. News: Covid-19: Studies Indicate Pfizer-BioNTech Vaccine Protects Against the Most Severe Outcomes of Some Virus Variants . . 2021-05-05 . 2024-12-14.
  6. Web site: Hannah Devlin, Julia Kollewe . BioNTech says it could tweak Covid vaccine in 100 days if needed . . 2021-11-26 . 2024-12-14.
  7. Web site: 13 November 2020 . BioNTech's founders: scientist couple in global spotlight . 22 December 2020. . en.
  8. Web site: Prof. Christopher Huber . BioNTech . 5 August 2021.
  9. Web site: Chris Edwards . 2021-09-24 . The Triumph of Biotechnology and Private Capital . 2024-12-15 . Cato Institute.
  10. Web site: SEC Filing BioNTech. 130. 28 December 2020 . investors.biontech.de.
  11. News: Joe Miller, Clive Cookson . 2020-12-16 . FT People of the Year: BioNTech's Ugur Sahin and Ozlem Tureci . 2024-08-26 . Financial Times.
  12. News: Ben Stupples . 2022-03-02 . Helmut Jeggle: vom Strüngmann-Vermögen zum eigenen Family Office . 2024-12-15 . Capital.
  13. Web site: TheraCode to Acquire JPT Peptide Technologies . GenomeWeb . 7 December 2020 . 11 May 2009.
  14. News: 2022 . Prize Winners of the Paul Ehrlich and Ludwig Darmstaedter Prize 2022 . 2024-12-15 . Goethe University Frankfurt.
  15. Web site: Beth Mole . 2 October 2023 . After being demoted and forced to retire, mRNA researcher wins Nobel . 3 October 2023 . . en-us.
  16. Web site: 9 November 2020 . Magyar kutató, hányatatott sorsú szabadalma is kellett a most bejelentett vakcinához . 22 December 2020 . forbes.hu . hu . 26 January 2021 . https://web.archive.org/web/20210126171032/https://forbes.hu/uzlet/hanyatatott-sorsu-magyar-szabadalom-is-kellett-a-most-bejelentett-vakcinahoz/ . dead .
  17. Piotr Rzymski . 2023-12-07 . 2024-12-15 . The pivotal role of uridine modifications in the development of mRNA technology . Journal of Medical Sciences . e938 . 10.20883/medical.e938 . en. free .
  18. Web site: Nick Paul Taylor . Genentech lays $310M wager on BioNTech's mRNA cancer vaccine platform . FierceBiotech . 7 December 2020 . 21 September 2016.
  19. Web site: Biontech sammelt Millionenbetrag ein . . 2019-12-06 . 2019-07-10.
  20. Web site: Sylke Maas . John Woolford . Jasmina Alatovic . 2018-08-16 . BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza . live . https://archive.today/20211208155206/https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-signs-collaboration-agreement-pfizer-develop-mrna-based . 2021-12-08 . 2022-12-28 . BioNTech.
  21. Web site: Nick Paul Taylor . 2019-07-09 . BioNTech raises $325M series B round to advance cancer pipeline . live . https://web.archive.org/web/20221228204017/https://www.fiercebiotech.com/biotech/biontech-raises-325m-b-round-to-advance-cancer-pipeline . 2022-12-28 . 2022-12-28 . Fierce Biotech . en.
  22. Web site: Callum Keown, Lina Saigol . 2020-12-08 . Here are 5 things to know about BioNTech and the married couple behind the COVID-19 vaccine developed with Pfizer . live . https://web.archive.org/web/20221229025620/https://www.marketwatch.com/story/everything-you-need-to-know-about-biontech-and-the-married-couple-behind-the-covid-19-vaccine-at-the-front-of-a-global-race-11605032681 . 2022-12-29 . 2022-12-29 . . EN-US.
  23. Web site: BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs. 4 September 2019. 27 December 2020. BioNTech.
  24. Web site: en. . European Investment Bank provides funding of €50 million to BioNTech as part of the Investment Plan for Europe . . 17 December 2019 . 21 November 2020.
  25. News: Rebecca Spalding, Joshua Franklin . Germany's BioNTech raises $150 million in smaller-than-planned U.S. IPO amid market volatility . 7 December 2020 . Reuters . 9 October 2019.
  26. Web site: 2020 . Aiming to address the global coronavirus pandemic: Project Lightspeed . 13 December 2020 . BioNTech.
  27. News: Ludwig Burger . 15 March 2020. BioNTech in China alliance with Fosun over coronavirus vaccine candidate. Reuters. 2021-07-22.
  28. Web site: Fabian Schmidt . Germany to start coronavirus vaccine trials . 2020-04-22 . 2024-12-15 . Deutsche Welle.
  29. Web site: BioNTech moves to head of pack for COVID-19 vaccine with EU finance. 2021-06-30. European Investment Bank. en.
  30. March 2004. EU forks out € 50 million to clean Internet. Network Security. 2004. 3. 3. 10.1016/s1353-4858(04)00047-9. 1353-4858. subscription.
  31. Web site: BioNTech moves to head of pack for COVID-19 vaccine with EU finance. 3 February 2021. European Investment Bank. en.
  32. Web site: en. . Investment Plan for Europe: European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing . . 11 June 2020 . 21 November 2020.
  33. Web site: 15 September 2020 . BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162 . 3 February 2021 . GlobeNewswire News Room.
  34. News: Ludwig Burger . 29 June 2020 . Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech . . Frankfurt . 2 August 2020.
  35. Web site: 2 December 2020 . Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine . 2 December 2020 . Government of the United Kingdom . en.
  36. Web site: 2 December 2020 . UK medicines regulator gives approval for first UK COVID-19 vaccine . 2 December 2020 . Government of the United Kingdom . en.
  37. Web site: 21 December 2020. Commission approves BioNTech/Pfizer vaccine. 22 December 2020. Politico. en-US.
  38. Web site: 2021-08-05 . Biontech: An der Börse über 100 Milliarden Dollar wert . 2024-09-02 . . de.
  39. News: Elisabeth Dostert . Der Boom ist vorbei . . 2024-05-11 . 24.
  40. Web site: Thomas Schulz . Wie Biontech zum zweiten Mal Medizingeschichte schreiben will . . 2024-02-04 . 2024-12-14.
  41. Web site: Christina Hohmann-Jeddi . mRNA-Vakzine: Biontech startet Phase-II-Studie mit Krebsimpfstoff . Pharmazeutische Zeitung . 2021-06-22 . de . 2024-12-14.
  42. Web site: Jürgen Salz . Biontech: "Das würde ein neues Zeitalter in der Krebstherapie einleiten" . . 2024-04-12 . 2024-12-14.
  43. Web site: Michael Barck . BioNTech: FDA erteilt Breakthrough-Therapy-Status für Krebsmittel BNT323 . de . 2023-12-21 . 4Investors . 2024-12-14.
  44. News: Biontech forciert Krebsmittel-Entwicklung . . 2024-01-23 . 9.
  45. News: Siegfried Hofmann . Die mRNA-Revolution . . 2021-08-23 . 22.
  46. BioNTech Completes Acquisition of InstaDeep . 2023-07-31 . en-US . 2023-08-01 . Yahoo Finance.
  47. News: Ludwig Burger . Pratik Jain . Leroy Leo . 2023-01-10 . Germany's BioNTech buys British AI startup InstaDeep . Reuters.
  48. News: Nicola Meier . Alles im Kasten . . 2024-03-22 . 10–23.
  49. News: Ralf Heidenreich . 70 Forscher, ein Gerücht . Bürstädter Zeitung . 2023-07-19 . 8.
  50. News: . Impfung gegen den Krebs . . 2023-02-18 . 92–94.
  51. Web site: Sebastian Balzter . Biontech auf Britisch . . 2023-01-27 . de . 2024-12-14.
  52. Web site: 治汇网络科技(上海)有限公司-高端网站建设 . Triastek announces research collaboration and platform technology license agreement with BioNTech to Advance 3D Printed Oral RNA Therapeutics-News-三迭纪 TRIASTEK . https://web.archive.org/web/20250115191216/http://www.triastek.com/detail/36.html . 2025-01-15 . 2025-06-29 . www.triastek.com . ko.
  53. 2024 . 12 EU-Politik: Kommunale Abwasserrichtlinie . UmweltBriefe . 28 . 12 . 12 . 10.5771/2941-0363-2024-12-12 . 1866-0037. subscription .
  54. News: Burger . Ludwig . 2025-06-12 . BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals . 2025-06-15 . Reuters . en.
  55. Web site: Huffman. Sarah. January 9, 2026. January 26, 2026. Penn, BioNTech launch $50M fund to support early-stage life sciences startups . live. Technical.ly.
  56. Web site: Bebauung der GFZ-Kaserne: Mehr Platz für Biontech? . Allgemeine Zeitung Mainz . 2020-05-25 . 2020-11-12.
  57. Web site: Locations . BioNTech . 2022-10-16.
  58. Web site: Ansgar Kretschmer . Biontech plant Impfstoff-Produktionsanlage in Afrika . Pharma + Food . 2021-10-27 . de . 2024-12-14.
  59. Web site: BioNTech buys German site from Novartis to boost vaccine output . . 2020-09-17 . 2024-12-14.
  60. Web site: 2023-12-17 . Thorsten Schüller . 2023-01-27 . Biontech: Wegen Rahmenbedingungen ab nach England . Deutsche Apothekerzeitung.
  61. Web site: Biontech kauft Krebsspezialisten in den USA . . de . 2021-07-19.
  62. Web site: Nora Menzel . Biontech übernimmt GMP-Produktionsanlage in Singapur . Pharma + Food . 2022-11-14 . de . 2024-12-14.
  63. Web site: Saheli Roy Choudhury . BioNTech to produce vaccines in Singapore, its new regional headquarters . . 2021-05-20 . en . 2024-12-14.
  64. Web site: Liam Mannix . mRNA giant wants changes to vaccine regulations to speed up new jabs . . 2022-10-07 . de . 2024-12-14.
  65. Web site: Biontech produziert Impfstoffe in RLP-Partnerland Ruanda . . 2023-12-18 . de . 2024-12-14.
  66. Web site: Moderna will seine erste Fabrik für Herstellung von mRNA-Impfstoffen in Afrika bauen . . 2022-03-08 . 2022-03-26.
  67. Web site: Our Board Members . BioNTech . 2024-12-14.
  68. U. Sahin . E. Derhovanessian . M. Miller . B. P. Kloke . P. Simon . M. Löwer . V. Bukur . A. D. Tadmor . U. Luxemburger . B. Schrörs . T. Omokoko . M. Vormehr . C. Albrecht . A. Paruzynski . A. N. Kuhn . J. Buck . S. Heesch . K. H. Schreeb . F. Müller . I. Ortseifer . I. Vogler . E. Godehardt . S. Attig . R. Rae . A. Breitkreuz . C. Tolliver . M. Suchan . G. Martic . A. Hohberger . P. Sorn . J. Diekmann . J. Ciesla . O. Waksmann . A. K. Brück . M. Witt . M. Zillgen . A. Rothermel . B. Kasemann . D. Langer . S. Bolte . M. Diken . S. Kreiter . R. Nemecek . C. Gebhardt . S. Grabbe . C. Höller . J. Utikal . C. Huber . C. Loquai . Ö. Türeci . Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer . . 547 . 7662 . 2017 . 222–226 . 10.1038/nature23003 . 28678784. 2017Natur.547..222S .
  69. Web site: N . Vishnu Priya . 2024-08-26 . BioNTech initiates global trials of mRNA-based lung cancer vaccine . 2025-07-20 . Clinical Trials Arena . en-US.
  70. News: Laetitia-Zarah Gerbes . Unbemerkter Fortschritt bei Biontech . . 2023-10-27 . 62.
  71. Web site: Krebs-Impfstoffe: Biontech plant Therapieansatz vor 2030 . 2023-11-26 . . de.
  72. Web site: BioNTech will 2026 Krebsmedikament auf Markt bringen . 2020-03-20 . 2023-11-26 . . de.
  73. Web site: Thorsten Winter . Krebs und Infektionen: Neuartige Impfstoffe als Ziel . . 2018-11-06 . 2024-12-14.
  74. Web site: Deutschland . Business Insider . 2021-06-01 . Knickt Biontech vor China ein? Taiwans Präsidentin erhebt Vorwürfe . 2025-04-08 . Business Insider . de-DE.
  75. News: Sander . Matthias . 2021-06-02 . Corona-Impfstoff: Helfen Private Taiwan nach Problemen mit China? . 2025-04-08 . Neue Zürcher Zeitung . de-CH . 0376-6829.
  76. Web site: Mascolo . Georg . 2021-02-18 . Corona-Impfstoff: Biontech wollte 54,08 Euro für eine Dosis . 2025-04-08 . Süddeutsche.de . de.
  77. Web site: Ärzteblatt . Deutscher Ärzteverlag GmbH, Redaktion Deutsches . 2021-02-19 . Biontech und Pfizer: Ursprungspreis betrug 54 Euro pro Impfdosis . 2025-04-08 . Deutsches Ärzteblatt . de.
  78. Web site: Kroh . Peter . 2021-02-19 . Abzock-Vorwurf gegen Biontech und Pfizer . 2025-04-08 . merkurist.de . de.
  79. Web site: Preise für mRNA-Impfstoffe steigen - Deutsche Apotheker Zeitung . 2025-04-08 . www.deutsche-apotheker-zeitung.de . de.